Announces

fitness

Echelon Fitness Announces Cyber Monday Flash Sale

Press release content from PR Newswire. The AP news staff was not involved in its creation.

CHATTANOOGA, Tenn., Nov. 30, 2020 /PRNewswire/ — Echelon Fitness is announcing a special, never before available, CYBER MONDAY FLASH SALE offering 25% OFF site-wide including equipment and accessories.

And for those ready to workout, Echelon’s immersive connected equipment is ready to ship. Customers who order on Cyber Monday can receive their products by Christmas.

Echelon offers connected bikes that give an immersive studio experience, smart rowers that take the rower down the best waterways in the world and reflect smart mirrors for personal training at the touch of a button. One Echelon membership allows up to five family members to enjoy all the benefits.

Two newest innovations include:

  • The smart Echelon Stride connected treadmill, with access to thousands of daily live and on-demand studio level classes with our world class instructors, easy set up and storage, built in wheels and a slim ten-inch-deep profile when folded.
  • Echelon’s limited edition Connect EX-1 LE in matte grey.The EX-1 LE offers sleek, aesthetic appeal while remaining equipped with the functionality necessary for effective rides for years to come.

There’s no better time to buy Echelon’s connected equipment! Details on offer, equipment and benefits of membership can be found at https://echelonfit.com/. **Memberships not included in the discount offer.

ABOUT ECHELON FITNESS

Echelon Fitness has been revolutionizing at-home connected fitness since deputing its first Connect Bike in 2017. What began as a mission to make healthy living attainable and accessible to all evolved into a line of innovative fitness solutions—as well as a thriving community. Ranging from sophisticated indoor cycling bikes, to touch-screen fitness mirrors and more, every product boasts thoughtful design and state-of-the-art technology, enabling people to exercise how they want, when they want and with who they want. By leveraging The Echelon Fit App and United Membership, members gain access to a variety of live and on-demand classes led by down-to-earth fitness instructors. Members can also use the app to track their performance against Echelon’s live leaderboard and overall progress, all while enjoying some healthy competition. For more information, visit https://echelonfit.com/.

View original content to download multimedia: http://www.prnewswire.com/news-releases/echelon-fitness-announces-cyber-monday-flash-sale-301181667.html

SOURCE Echelon Fit

Source Article

Read More
medicine

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

(MENAFN – Newsfile Corp) Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (” Lobe ” or the ” Company “) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (” NAC “) for the treatment of mild traumatic brain injury/concussion (” mTBI “) with post-traumatic stress disorder (” PTSD “). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

The Miller School of Medicine is an internationally recognized leader in medical research, ranked No. 39 among the top medical schools in the nation by Blue Ridge Institute for Medical Research. In 2019, the medical school submitted 1,968 research proposals and was awarded $149 million in research funding from the National Institutes of Health (NIH).

Advances in neuro-diagnostic assessment have revealed mild traumatic brain injury (concussion) is more common than previously thought and potentially associated with a host of negative health outcomes. The Centers for Disease Control (” CDC “) estimates that there are 3 million emergency room visits and over 230,000 hospitalizations due to TBI in any given year in the United States alone. Also, at the same time there are 5.3 million Americans living with the effects of mTBI (a 53% increase over ten years ago). The World Health Organization calls traumatic brain injury a “silent epidemic” that affects over 70 million individuals across the world. The United States Department of Defense estimates that over 345,000 individuals are affected by mTBI and that 20% of all service members who deploy suffer mTBI. mTBI and PTSD are significant health care issues that often co-occur and impact each other.

Dr. Hoffer, the principal investigator on the study, said, “This a very important extension of our work with NAC and other medicines to identify new treatments for mTBI and PTSD. We are hopeful that this new combination of psilocybin with NAC will lead us to better solutions for those suffering from mTBI and/or PTSD.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are very excited to begin the preclinical studies in collaboration with Dr.

Read More
medicine

Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol | News

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells. People with genetic variations that reduce PCSK9 function have lower LDL-C levels in the blood and a lower risk for major cardiovascular events. ION449 is a LIgand Conjugated Antisense (LICA) medicine being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.

The Phase 2b, randomized, double-blind, placebo-controlled trial will enroll approximately 108 participants, aged 18-75, who have LDL-C levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on blood cholesterol management. The primary objective is to assess the effect of different doses of ION449 on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy.  The study will evaluate three dose levels of ION449 versus placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints. Learn more about the trial at: https://clinicaltrials.gov/ct2/show/NCT04641299. 

In a Phase 1 study reported at the American Heart Association (AHA) Scientific Sessions on November 13, single subcutaneous doses of ION449 (AZD8233) demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90 percent and up to 70 percent, respectively, in subjects who had a baseline LDL-C between 100 and 190 mg/dL without concomitant statin therapy. Doses up to 120 mg were evaluated. ION449 was observed to be safe and well-tolerated at all dose levels. 

“Results from the Phase 1 study showed that ION449 potently reduces PCSK9 and LDL cholesterol. ION449 demonstrated best-in-class potential for PCSK9 inhibition and LDL-C reduction, supporting larger clinical trials that are now underway to further evaluate efficacy and safety,” said Sotirios “Sam” Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis. “The growing evidence supporting Ionis’ advanced LICA technology in cardiovascular disease holds promise for more effective approaches to lower LDL-C and to address cardiovascular disease, the leading cause of death worldwide.”

Dr. Tsimikas will provide an update on Ionis’ cardiovascular programs during Ionis’ Virtual Investor Day, Dec. 7, 2020, beginning at 12 p.m. EST.

Ionis earned a milestone payment of $20 million from AstraZeneca for the Phase 2b clinical trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiometabolic disease and cancer.

About Ionis Pharmaceuticals, Inc.

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our

Read More
dentist

Winnipeg Dental Practice Announces The Addition Of A New Dentist To The Company As They Continue To Grow & Expand – Press Release

Winnipeg Dental Practice Announces The Addition Of A New Dentist To The Company As They Continue To Grow & Expand

East Kildonan Dental Group, a fast-growing dental practice, is delighted to announce the addition of a new dentist to their ever-expanding team. The new dentist Dr. Ji Hun Han was born in Seoul, South Korea, and then moved to Winnipeg in 1998. He completed his D.M.D at the University of Manitoba Faculty of Dentistry in 2020 and his Bachelor of Science in Dentistry [B.Sc. (DENT)] with research on nanoparticles and their use in dentistry.

WINNIPEG, Canada East Kildonan Dental Group, a fast-growing dental practice, is delighted to announce the addition of a new dentist to their ever-expanding team. The new dentist Dr. Ji Hun Han was born in Seoul, South Korea, and then moved to Winnipeg in 1998. He completed his D.M.D at the University of Manitoba Faculty of Dentistry in 2020 and his Bachelor of Science in Dentistry [B.Sc. (DENT)] with research on nanoparticles and their use in dentistry.  

Although he enjoys all aspects of general dentistry, his driving passion is in the education of patients, with the aims of improving their oral health and preventing potential disease progression. He acknowledges that dental anxiety is a huge issue for many patients and has devised a range of strategies to help patients overcome their worries and concerns. He is interested in building a relationship with his patients so that they feel comfortable at their dental appointments, and is constantly working to improve his dental skills and knowledge through continuing education courses. Outside of his work, he enjoys rock climbing, playing soccer, and watching movies in his spare time. He is also fluent in English and Korean. 

“We are thrilled to have Dr. Han on our team, and we know that he will be a valuable asset to the business,” said dental colleague, Alex Serebnitski. “Dr. Han stood out from the crowd, has an excellent work ethic, and also demonstrates compassion and a nurturing attitude, which reflects our business ethos. We look forward to working with him for many years to come.” 

East Kildonan Dental is a locally owned and operated business in Winnipeg, Manitoba. The dental office was initially established in 1949, and over the years, has become a staple in East Kildonan. They take pride in the quality and variety of dental services they’ve offered to many friends and families over the years. 

With the addition of Dr. Han, East Kildonan Dental Group is extending its hours of operation. They can see more patients because of the new dentist. This business is continually working to serve the people of Winnipeg better, and their practice is now more accessible thanks to their growing team.

The new hours are Monday to Thursday, from 8 AM – 8 PM, and Friday to Saturday from 8:30 AM – 4:30 PM.

For more information about the company and the various dental services that they provide, visit their website at https://ekdentalgroup.com/.

https://www.ekdentalgroup.com/news/winnipeg-dental-practice-announces-addition-new-dentist-company-they-continue-grow-expand

https://local.google.com/place?id=5349875352996246164&use=posts&lpsid=3119218641341562462

https://g.page/EastKildonanDental?share

 

Media Contact
Company Name: East Kildonan Dental Group
Contact Person: Alex Serebnitski
Email: Send Email
Phone: 204-661-2614
Address:807 Henderson

Read More
medicine

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH). ION455 is the second medicine for the treatment of NASH that Ionis has partnered with AstraZeneca. The companies have also partnered on ION839 (AZD2693), which is designed to inhibit the production of patatin-like phospholipase domain-containing 3 (PNPLA3) protein, a major genetic determinant of NASH progression. Separately, Ionis is also developing a wholly owned NASH program. ION224 is designed to reduce the production of DGAT2, or diacylglycerol acyltransferase 2, for treating patients with NASH. ION224 is one of more than 20 medicines in the growing Ionis-owned pipeline that the company is prioritizing and preparing for commercialization.

NASH is the most severe form of nonalcoholic fatty liver disease (NAFLD). It is related to the epidemic of obesity, pre-diabetes and diabetes. Unlike liver disease caused by alcohol consumption, NAFLD is the result of an accumulation of fat in the liver, which can lead to inflammation and cirrhosis, an advanced scarring of the liver that prevents the liver from functioning normally. About 20 percent of NASH patients are reported to develop cirrhosis and 30 to 40 percent of patients with NASH cirrhosis experience liver-related death.i Currently, a liver transplant is the only treatment for advanced cirrhosis and liver failure. Because of the high prevalence of NASH, it has recently become the third most common indication for liver transplantation in the U.S.

“Today, there are no FDA-approved medicines to specifically treat nonalcoholic steatohepatitis. However, due in large part to the progress made by our cardio-metabolic franchise, three Ionis-discovered novel medicines are now in development. These are encouraging advances that we hope will one day bring therapeutic benefit to patients who have limited treatment options,” said Brett P. Monia, Ph.D., Ionis’ chief executive officer. 

ION455 is the fourth medicine to reach development in partnership with AstraZeneca. Ionis earned $30 million from AstraZeneca for licensing ION455 and is eligible to earn up to $300 million in milestone payments plus royalties on net sales. AstraZeneca will have responsibility for further development of ION455, including regulatory filings, and commercialization.

In addition to NASH, Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiovascular disease and cancer.

Ionis’ Forward-looking Statement

This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of ION455, ION839 (AZD2693), ION224 and Ionis’ technologies and products in development. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for

Read More
medicine

The Alliance for Regenerative Medicine Announces Record Sector Financing in 2020

The regenerative medicine sector attracted $15.9 billion in financing through just the first three quarters of the year, shattering the previous record of $13.5 billion

Washington, DC, Nov. 19, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Global financing for the regenerative medicine and advanced therapy sector set an annual record of $15.9 billion through just the first three quarters of 2020, according to data released today by the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines.

Despite the COVID-19 pandemic, financing for the cell, gene, and tissue-based therapies sector surpassed the previous record of $13.5 billion set during full-year 2018.

“There is strength across all types of investment and stages of the pipeline, from early-stage cell-based immuno-oncology to late-stage gene therapies,” said Janet Lambert, CEO of ARM. “The outlook for patients has never been brighter.”

Investors remain bullish about the promise of profound, durable, and possibly curative regenerative medicines to treat a range of diseases and disorders.

Public financing continues to drive the sector, through both IPOs ($2.8 billion YTD) and follow-on financings ($5.7 billion YTD). At $4.1 billion year-to-date, venture capital financing is also on track to surpass the previous record of $4.3 billion set in 2019.

“The rapid advancement of the science behind regenerative medicine makes this a very dynamic time for investors and a hopeful time for patients,” said Jason Rhodes, a partner at Atlas Venture. “The breadth of approaches now available — from CRISPR to CAR-Ts to lentiviruses and non-viral gene therapies — enables us to pick the right tool for the specific biology that we’re addressing.”

Highlights from ARM’s third-quarter 2020 data include:

Gene therapy financing was $3.5B in Q3 2020 and $12 billion YTD, up 178% and 114% from 2019 levels respectively; cell therapy financing reached $3 billion in Q3 2020 and $11 billion YTD, up 97% and 242%, respectively; tissue-based therapy financing was $226 million in Q3 2020 and $311 million YTD, up 11% and 311% respectively.*

At the end of Q3 2020, there were 1,109 regenerative medicine clinical trials ongoing worldwide – 373 in gene therapy, 492 in cell-based immuno-oncology, 202 in cell therapy, and 42 in tissue-based therapies.

Of the 1,109 clinical trials, 388 target more prevalent diseases, including prevalent cancers (159), cardiovascular disease (35), diseases of the central nervous system (33), infectious diseases including COVID-19 (38), and diabetes (17).

There are 97 ongoing Phase 3 clinical trials, with regulatory decisions expected in the coming months in the US and Europe for several product candidates across cell, gene, and tissue-based therapies; cell-based immuno-oncology now comprises more than half of the 418 Phase 1 trials.

There are 1,026 regenerative medicine and advanced therapy developers active globally, up from 1,001 in our previous report covering the first half of 2020. Of the current total, 536 are active in gene therapy, 641 are active in cell therapy, and 135 are active in tissue-based therapies.

* Some companies utilize multiple technology types, and financings for

Read More
medicine

Baylor Scott & White Health announces new affiliations with Baylor College of Medicine and Texas A&M University to further expand the pipeline of exceptional clinical talent for Texas

Baylor Scott & White Health, the largest not-for-profit health system in the state of Texas, today announced two separate academic affiliations: a new affiliation with Baylor College of Medicine and an expanded affiliation with its long-time partner Texas A&M University. Both alliances are aimed at training future clinicians and developing programs that advance high-quality care and healthcare innovation. 

“We believe these long-term partnerships will ensure that our patients will have access to breakthrough medical discoveries and cutting-edge treatments from world-class physicians for generations to come,” said Peter J. McCanna, president, Baylor Scott & White.  

Baylor Scott & White offers the full continuum of care, from primary to award-winning specialty care, through an integrated care delivery network of 52 hospitals and more than 1,100 access points including flagship academic medical centers in Dallas and Temple. Baylor Scott & White extends investigational expertise across more than 50 medical specialties through Baylor Scott & White Research Institute, which provides the business and regulatory infrastructure to accelerate medical breakthroughs and innovative new treatment models. Baylor Scott & White Research Institute oversees nearly 2,000 active trials each year. 

Establishing a new Baylor College of Medicine regional medical school campus in Temple 

Baylor Scott & White and Baylor College of Medicine today announce a new affiliation to enhance the organizations’ collective impact on the statewide effort to train more students to become physicians.  

Additionally, the affiliation will allow for opportunities for expanded research and program development, with the ultimate goal of improving health and healthcare for Texans. 

The new 20-year relationship will be anchored by the development of a progressive four-year regional medical school campus in Temple, Texas, where Baylor College of Medicine will offer a curriculum highlighted by an approach that fully integrates health system and university resources to deliver adaptive and personalized medical education.  

“This is a great opportunity to expand Baylor College of Medicine’s outstanding medical education programs to a regional medical school campus,” said Dr. Paul Klotman, president, CEO and executive dean of Baylor College of Medicine. “We are looking forward to being in Temple.”  

Through a holistic recruiting process, Baylor College of Medicine focuses on recruiting a diverse class of students who are from and reflective of the communities that Baylor Scott & White serves. An inaugural class of 40 medical students is anticipated to begin training in Fall 2023. The campus will increase by 40 students a year over four years. The medical school is excited to welcome 160 more students to experience the caliber of education offered by Baylor College of Medicine. 

Baylor College of Medicine will strive to maintain a high percentage of Texas residents in the medical school. The goal of the new affiliation is to further expand the physician workforce pipeline for Texas with graduates having the opportunity to serve as future leaders in communities and providing outstanding clinical care for the people of Texas.  

The regional medical school campus in Temple will be overseen by the Baylor College of Medicine School of Medicine Dean, and

Read More
fitness

ClubReady Announces Partnership With Factor4 to Provide Gift Card Program to Fitness Studios

ST. LOUIS, Nov. 17, 2020 /PRNewswire/ — ClubReady, the leading provider of full-suite studio fitness and wellness club management software, today announced it will launch an integration with Factor4, the leading provider of gift card and loyalty solutions, this October. Amid the COVID-19 crisis, the global market for gift cards is estimated at $1 trillion this year and is projected to reach a revised size of $2.7 trillion by 2027. This integration will allow fitness studios, and their members, to benefit from this preferred and profitable method of gifting and payment.

“The ClubReady and Factor4 integration will provide our fitness studios customers access to a new revenue stream while adding value for their members,” said Fred Elias, Vice President of Business Development at ClubReady. “The gift program will also help studios acquire new members,” he explained. Studios can operate their gift card program out of a single management portal to view transaction data and trends. Factor4’s online gift card solution will enable studios to have custom branded pages integrated with ClubReady so members can purchase digital and plastic gift cards seamlessly from their websites. This is especially important considering the number of cards purchased online soared 57% in the first 6 months of this year compared to the first half of 2019, while purchases of digital gift cards jumped 61% comparatively, according to InComm.  

“We are excited to partner with ClubReady and to provide fitness studios with a new revenue source that will help them recover from the COVID-19 closures that impacted the fitness industry,” said Dan Battista, Factor4 CEO. “Our solution complies with social distancing standards by enabling contactless delivery of gift cards via email and text, as well as the ability for members to pay by phone. Factor4 will help fitness studios use gift cards to attract new members and retain existing members.” 

This integration provides fitness studios with versatility in developing their gift card programs. ClubReady and Factor4 estimate an implementation period of two to three weeks. With the integration complete, studios can launch their gift card program in time for the holiday season. Gift cards have been the most popular holiday gift to give and receive for 13 consecutive years. Learn more about this solution here.

Factor4

Factor4, LLC was formed by four payment service experts to provide the premier gift card and loyalty solution. The founders’ strength comes from their combined industry expertise and extensive network. Factor4’s strength is from its best-in-class, proprietary platform, technology, integrations and team. The RewardOS API provides effortless, feature-rich integration to a wide range of point-of-sale devices. Factor4 boasts the most integrations of all gift and loyalty providers. Factor4 serves over 13,000 customers and growing. For more information, visit https://www.factor4gift.com/.

ClubReady

ClubReady is the leading provider of full-suite studio fitness and wellness club management software and services. Founded in 2009, ClubReady has been committed to building the studio fitness business of the future.  The ClubReady Fitness Management Platform provides clients a full membership management and engagement

Read More
medicine

Michigan Medicine announces restrictions to visitors as statewide COVID-19 cases surge

ANN ARBOR – Michigan Medicine announced Monday it has added visitor restrictions at its hospitals and clinics to curb the spread of COVID-19 and to protect patients and staff.

Visitors are no longer allowed in the adult emergency department, except when medically necessary.

Its visitor policy at its adult hospitals and C.S. Mott Children’s Hospital remains unchanged: one visitor per day per adult and two for pediatric patients. Visitors, including family, are required to wear a face covering that covers their nose and mouth at all Michigan Medicine properties, including inside a patient’s room. Patients who are able to tolerate a mask must wear one in the presence of a health care worker.

No visitors will be allowed in clinics for adult patients unless the patient has a physical or cognitive impairment that requires assistance. For pediatric patients, one primary caregiver is allowed at an appointment, unless an additional assistant or aide is required.

Exceptions to the new restrictions include end-of-life care, labor and delivery and other scenarios which are listed here.

 Like what you’re reading? Sign up for our email newsletter here!

“We recognize the critical role that visitors – families and friends – play in the well-being of our patients. However, as the spread of COVID-19 hits record-setting levels across the state, we need to minimize the risk of transmission,” Laraine Washer, Michigan Medicine’s medical director of infection prevention and epidemiology, said in a statement.

“Our top priority is the safety of our patients and our staff. We hope that by adding these restrictions, we will better protect everyone from COVID-19,” Washer continued. “We need to continue to keep our Michigan Medicine facilities safe for all of our patients.”

Since the pandemic began in March, Michigan Medicine has been taking steps to keep staff and patients safe, including screening patients for symptoms, cleaning and disinfecting facilities, moving furniture to observe social distancing and following the latest guidelines to minimize infections.

“Many people in our facilities are very sick or have weakened immune systems, which places them at higher risk,” Washer said in a statement. “Limiting visitors and requiring a mask at all times will help reduce the spread of infection.”

Related reading:

Copyright 2020 by WDIV ClickOnDetroit – All rights reserved.

Source Article

Read More
medicine

Schwazze, Formerly Operating as Medicine Man Technologies, Inc., Provides Business Update and Announces Strong Third Quarter 2020 Financial Results

DENVER–(BUSINESS WIRE)–Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX:SHWZ) (“Schwazze ” or “the Company”), today provided a business update and announced strong financial results for its third quarter ended September 30, 2020.

Justin Dye, Chairman and Chief Executive Officer of Schwazze shared, “We are pleased with our progress in the third quarter. We continued to grow revenue and meaningfully narrow our net loss. Our third quarter performance demonstrates the team’s ability to implement our operating playbook and successfully integrate strategically attractive and accretive acquisitions such as Mesa Organics and Purplebee’s, which have proven to be an excellent strategic fit, into our operations.”

Dye continued, “We are eager to complete our acquisitions of Star Buds’ 14 Colorado locations during the fourth quarter. Star Buds is one of the most recognized and successful retail cannabis operators in North America. These acquisitions position us to become a cannabis leader in Colorado by combining their industry expertise with our best-in-class playbook. Together, we are creating the next era of cannabis that lowers the barrier of acceptance for mainstream America and accelerates innovation in health, happiness and quality of life for consumers.”

Business Update

  • On November 5, 2020, the Company announced that it has received satisfactory proof of funds acknowledgement from Star Buds in anticipation of closing the pending transactions. This acknowledgment enables companies to begin preparing for a fourth quarter 2020 closing of the acquisitions of 13 retail operations located throughout the Colorado front-range and one cultivation facility in Denver.
    • Star Buds is one of the most recognized and successful retail cannabis operators in North America based on revenue-per-location and profit. Upon completion of this transaction, the Company will be one the first publicly traded companies with full seed to sale operations in Colorado consisting of 17 dispensaries, manufacturing, and cultivation.
    • Based on the consolidated, unaudited 2019 results the Company received from Star Buds, these acquisitions collectively earned approximately $50M in revenue with a strong EBITDA margin.
    • The proforma revenue for the combined companies for 2020 will be approximately $90M and the combined companies will be profitable and cash flow positive after the completion of the acquisition.
  • On September 9, 2020, the Company announced that Nirup Krishnamurthy, Chief Integration and Information Officer, was named Chief Operating Officer, and Jeff Garwood, former GE executive, was appointed to the Schwazze Board of Directors.
    • Nirup Krishnamurthy has since assumed oversight of Schwazze’s business units including retail, manufacturing, cultivation, wholesale sales, and marketing to drive operational excellence throughout field operations. He has also continued to be responsible for the alignment and prioritization of the ongoing integration of the Company’s acquisitions and for driving technology innovation across the organization. Krishnamurthy joined Schwazze earlier this year, bringing more than 25 years of experience in operations, innovation, technology, integration and M&A at Fortune 500 companies including United Airlines, Northern Trust Bank and former grocery retailer The Great Atlantic & Pacific Tea Company (A&P).
    • Jeff Garwood is a recognized visionary business leader bringing 30 years of extensive experience across
Read More